Increased hepatotoxicity of tumor necrosis factor–related apoptosis-inducing ligand in diseased human liver

Abstract

These results suggest that clinical trials should be performed with great caution when TRAIL is combined with chemotherapy or administered to patients with inflammatory liver diseases.